Abstract
Allogenic haematological stem cell transplantation (allo-SCT) from a human leukocyte antigen (HLA) matched related or unrelated donor is used as a curative therapy for a large number of malignant and non-malignant haematological diseases. The curative effect of allo-SCT is achieved by graft versus leukaemia effect while the downside of the graft versus patient activity is the graft-versus-host-disease (GVHD), a major reason for mortality and morbidity. The search of articles for this review had been accomplished using Ovid, Medline, Embase, Pubmed and was supplemented by retrieving cross references also. Electronic literature search for English language articles with full text access was performed using graft versus host disease, ocular, management, dry eyes as key words. This review has been intended to explicate the classification, pathogenesis, risk factors and management of ocular graft versus host disease.
Highlights
GVHD is a disease related to allogenic haematological stem cell transplantation
These proteins are usually consisting of highly polymorphic human leukocyte antigen (HLA) which are encoded by the major histocompatibility complex (MHC)
Even after giving thorough consideration to HLA matching acute GVHD can develop in significant number of patients due to minor histocompatibility antigen [3] [4]
Summary
GVHD is a disease related to allogenic haematological stem cell transplantation. This disease is due to T cell response of donor cells to the proteins of recipient host cells which are genetically defined. These proteins are usually consisting of highly polymorphic HLA which are encoded by the major histocompatibility complex (MHC). Electronic literature search for English language articles with full text access was performed using graft versus host disease, ocular, management, dry eyes as key words. This review has been intended to explicate the classification, pathogenesis, risk factors and management of ocular graft versus host disease
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
